MUC4 mutations promote a thrombotic phenotype in patients with paroxysmal nocturnal haemoglobinuria by increasing the deposition of terminal complement

Abstract

Background: Thrombosis is a common complication in paroxysmal nocturnal haemoglobinuria (PNH) patients, but primary prevention remains controversial. Identifying high-risk individuals could enable risk-stratified prophylactic anticoagulation strategies.

Methods: We analyzed clinical data from PNH patients with or without thrombosis, including MUC4 mutation status and serum complement C5b-9 levels. Complement deposition assays and a murine lower limb deep vein thrombosis model were used to investigate the role of MUC4 mutation in thrombotic risk and explore the underlying mechanism involving terminal complement activation in PNH patients. Therapeutic interventions with low molecular weight heparin (LMWH) were tested in vivo.

Results: We found that PNH patients with MUC4 mutations have a higher incidence of thrombotic events (TEs) and MUC4 mutation is an independent risk factor for TE in PNH patients. Additionally, PNH patients with acute thrombosis had elevated serum complement C5b-9 levels, and complement deposition experiments further confirmed the abnormal activation and excessive deposition of C5b-9 as the basis for the thrombotic tendency in PNH patients. By constructing a mouse model of lower limb deep vein thrombosis, we confirmed the thrombotic tendency in a PNH mouse model and that MUC4 deficiency further promoted the thrombotic phenotype of the mice. Moreover, we found that MUC4 knockdown promoted the deposition of C5b-9 on the cell surface, indicating that a lack of MUC4 expression facilitates the deposition of C5b-9. Finally, in vivo drug administration experiments demonstrated that prophylactic anticoagulation with LMWH significantly reduced both the incidence of thrombosis and thrombus length in murine models.

Conclusion: MUC4 mutations promote the thrombotic phenotype in PNH patients by increasing the deposition of terminal complement. In PNH patients with concomitant MUC4 mutations, the risk of TEs is further elevated. The potential role of early complement inhibitor therapy in reducing this heightened thrombotic risk, as well as the value of prophylactic LMWH therapy as a potential option for patients who are unable to receive complement inhibitor treatment, warrants further study and prospective validation.

Keywords

C5b-9 / MUC4 / paroxysmal nocturnal haemoglobinuria / thrombosis

References

[1] Brodsky RA, Mukhina GL, Nelson KL, et al. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood. 1999; 93(5): 1749-1756.

[2] Apostolidou E, Georgoulis V, Leonardos D, et al. Paroxysmal nocturnal hemoglobinuria: unraveling its molecular pathogenesis and advancing targeted therapeutic strategies. Diseases. 2025; 13(9): 298.

[3] Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013; 121(25): 4985-4996.

[4] Waheed A, Shammo J, Dingli D. Paroxysmal nocturnal hemoglobinuria: review of the patient experience and treatment landscape. Blood Rev. 2024; 64:101158.

[5] Nishimura JI. Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab. Rinsho Ketsueki. 2018; 59(8): 1042-1047.

[6] Panse J. Paroxysmal nocturnal hemoglobinuria: where we stand. Am J Hematol. 2023; 98(Suppl 4): S20-S32.

[7] Kokoris S, Polyviou A, Evangelidis P, et al. Thrombosis in paroxysmal nocturnal hemoglobinuria (PNH): from pathogenesis to treatment. Int J Mol Sci. 2024; 25(22):12104.

[8] Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol. 2011; 153(6): 709-720.

[9] Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol. 2008; 6(4): 347-353.

[10] Jang JH, Kim JS, Yoon SS, et al. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH Registry. J Korean Med Sci. 2016; 31(2): 214-221.

[11] Huang Y, Liu X, Chen F, et al. Prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2019; 98(10): 2283-2291.

[12] Li L, Wang H, Liu H, et al. Gene mutations associated with thrombosis detected by whole-exome sequencing in paroxysmal nocturnal hemoglobinuria. Int J Lab Hematol. 2019; 41(3): 424-432.

[13] Moniaux N, Escande F, Batra SK, et al. Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem. 2000; 267(14): 4536-4544.

[14] Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008; 22(4): 966-981.

[15] Chen Y, Liu H, Zeng L, et al. SUZ12 participates in the proliferation of PNH clones by regulating histone H3K27me3 levels. J Leukoc Biol. 2022; 112(2): 243-255.

[16] Chen Y, Meng X, Wang Y, et al. Several implications for the pathogenesis and treatment of thrombosis in PNH patients according to multiomics analysis. J Transl Med. 2024; 22(1): 129.

[17] Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016; 2016(1): 208-216.

[18] Zeng L, Liu H, Liu Z, et al. Defected lipid rafts suppress cavin1-dependent IFN-α signaling endosome in paroxysmal nocturnal hemoglobinuria. Int Immunopharmacol. 2023; 115:109468.

[19] Chen Y, Liu H, Zeng L, et al. A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis. Exp Hematol Oncol. 2022; 11(1): 1.

[20] Chaturvedi S, Braunstein EM, Yuan X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020; 135(4): 239-251.

[21] Jahan R, Macha MA, Rachagani S, et al. Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(8): 2538-2549.

[22] Harboe M, Ulvund G, Vien L, et al. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004; 138(3): 439-446.

[23] Karg A, Dinç ZA, Başok O, et al. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract. 2006; 202(8): 577-583.

[24] Ponnusamy MP, Lakshmanan I, Jain M, et al. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. 2010; 29(42): 5741-5754.

[25] Komatsu M, Carraway CA, Fregien NL, et al. Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex. J Biol Chem. 1997; 272(52): 33245-33254.

[26] Xia P, Choi AH, Deng Z, et al. Cell membrane-anchored MUC4 promotes tumorigenicity in epithelial carcinomas. Oncotarget. 2017; 8(8): 14147-14157.

[27] Dhawan R, Ahluwalia J, Malhotra P, et al. Markers of thrombin generation and inflammation in patients with paroxysmal nocturnal hemoglobinuria. Indian J Hematol Blood Transfus. 2021; 37(2): 204-209.

[28] Patriquin CJ, Kiss T, Caplan S, et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol. 2019; 102(1): 36-52.

[29] Schmidt CQ, Schrezenmeier H, Kavanagh D. Complement and the prothrombotic state. Blood. 2022; 139(13): 1954-1972.

[30] Ueda Y, Chou WC, Goh YT, et al. Prevention and management of thromboembolism in patients with paroxysmal nocturnal hemoglobinuria in Asia: a narrative review. Int J Mol Sci. 2025; 26(6): 2504.

[31] Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021; 137(10): 1304-1309.

[32] Sicre de Fontbrune F, Peffault de Latour R. Ten years of clinical experience with eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Semin Hematol. 2018; 55(3): 124-129.

[33] Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110(12): 4123-4128.

[34] Gerber GF, Brodsky RA. ADP: the missing link between thrombosis and hemolysis. Blood Adv. 2023; 7(20): 6364-6366.

[35] Mannes M, Pechtl V, Hafner S, et al. Complement and platelets: prothrombotic cell activation requires membrane attack complex-induced release of danger signals. Blood Adv. 2023; 7(20): 6367-6380.

[36] Montz H, Koch KC, Zierz R, et al. The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunology. 1991; 74(3): 373-379.

[37] Wiedmer T, Hall SE, Ortel TL, et al. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993; 82(4): 1192-1196.

[38] Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol. 2020; 27(5): 341-352.

[39] Hugel B, Socié G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999; 93(10): 3451-3456.

[40] Devos T, Meers S, Boeckx N, et al. Diagnosis and management of PNH: review and recommendations from a Belgian expert panel. Eur J Haematol. 2018; 101(6): 737-749.

[41] Sloand EM, Pfannes L, Scheinberg P, et al. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol. 2008; 36(12): 1616-1624.

[42] Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 2008; 38(1): 9-14.

[43] Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets. 2001; 12(5): 261-273.

[44] Höchsmann B, Peffault de Latour R, Hill A, et al. Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry. Ann Hematol. 2023; 102(11): 2979-2988.

[45] Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020; 99(7): 1505-1514.

[46] Risitano AM, Peffault de Latour R. How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol. 2022; 196(2): 288-303.

[47] Croden J, Oliver M, Wu CM. Anticoagulation use and patient outcomes in paroxysmal nocturnal hemoglobinuria: a province-wide retrospective review. Blood. 2023; 142(Supplement 1): 1283.

[48] Gurnari C, Awada H, Pagliuca S, et al. Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis. Blood. 2024; 144(2): 145-155.

[49] Han B, Liu H, He G, et al. A real-world, multi-center, prospective, observational study for paroxysmal nocturnal hemoglobinuria (PNH) in China: preliminary results. EHA poster. 2025:PB2793.

[50] Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Zhonghua Xue Ye Xue Za Zhi. 2024; 45(8): 727-737.

[51] Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003; 102(10): 3587-3591.

[52] Araten DJ, Notaro R, Thaler HT, et al. Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica. 2012; 97(3): 344-352.

[53] Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. Ther Adv Hematol. 2017; 8(3): 119-126.

[54] Hosen N, Takamori H, Nishimura J, et al. Reference Guide on Clinical Practice for Paroxysmal Nocturnal Hemoglobinuria (2022 Revision). 2023. http://zoketsushogaihan.umin.jp/file/2022/Paroxysmal_nocturnal_hemoglobinuria.pdf. Available from:

[55] Schubert J, Bettleheim P, Brümmendorf TH, et al. Paroxysmal Nocturnal Haemoglobinuria (PNH). Guideline: Recommendations of the Professional Society for Diagnostics and Therapy for Haematological and Oncological Diseases. 2019. https://www.onkopedia.com/de/onkopedia/guidelines/paroxysmale-naechtliche-haemoglobinurie-pnh/@@guideline/html/index.html. Available from:

[56] Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res. 2011; 127(Suppl 2): S5-S12.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.